Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cytonus Therapeutics to Present Cargocyte™ Drug-Delivery Data at the ASGCT 25th Annual Meeting
Details : Cargocytes armed with interleukin 12 (CA-IL-12) can be engineered to actively home, migrate, and penetrate deep into specific disease foci and synthesize biologically active therapeutic within the target tissues, hours after intravenous administration.
Product Name : CA-IL-12
Product Type : Protein
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results highlight the capabilities of Cytonus’ innovative Cargocyte™ platform in addressing solid tumor penetration challenges. Importantly, Cargocytes offer localized delivery of potent immunotherapies in a controlled manner to enhance their safety ...
Product Name : CA-IL-12
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : CA-IL-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable